← Back to Search

Monoclonal Antibodies

CDX-527 for Non-Small Cell Lung Cancer

Phase 1
Waitlist Available
Research Sponsored by Celldex Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Receipt of all standard therapies for the tumor type
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 8 weeks starting with first dose until disease progression, assessed up to approximately 1-2 years.
Awards & highlights

Study Summary

This trial is testing a new cancer treatment on patients with selected solid tumors. The treatment will be given in escalating doses to determine a safe and effective dose. The trial will be conducted at multiple center and the treatment's effectiveness will be expanded.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Bile Duct Cancer
  • Peritoneal Carcinoma
  • Head and Neck Cancers
  • Colorectal Cancer
  • Liver Tumors
  • Kidney Cancer
  • Stomach Cancer
  • Esophageal Cancer
  • Breast Cancer
  • Solid Tumors
  • Bladder Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have already received all of the typical treatments for your type of tumor.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 8 weeks starting with first dose until disease progression, assessed up to approximately 1-2 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 8 weeks starting with first dose until disease progression, assessed up to approximately 1-2 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and Tolerability of CDX-527 as assessed by CTCAE v5.0
Secondary outcome measures
Clinical Benefit Rate
Duration of Response
Immunogenicity Evaluation
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: CDX-527Experimental Treatment1 Intervention
Dose-escalation phase: Eligible patients will receive CDX-527 treatment based on cohort assigned until progression or intolerance. Expansion phase: Patients will receive CDX-527 at the dose level(s) chosen during the escalation phase.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CDX-527
2020
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

Celldex TherapeuticsLead Sponsor
60 Previous Clinical Trials
3,817 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still opportunity for individuals to join this clinical experiment?

"According to clinicaltrials.gov, the recruitment period for this medical study has closed as of November 29th 2022; it was originally posted on August 4th 2020. Nevertheless, there are over 5400 other trials that currently need participants."

Answered by AI

How many centers are actively overseeing this clinical trial?

"Presently, patients are being recruited from 5 distinct trial sites, which are located in Omaha, Durham and Portland as well as two other locales. To cut down on travel related expenses it is advisable to select the research centre closest to you if you decide to partake."

Answered by AI

To what degree is CDX-527 hazardous to human health?

"Data collected on CDX-527's safety is limited, so we rated it a 1 out of 3. This treatment currently resides in Phase 1 trials and has yet to be thoroughly evaluated for efficacy and safety."

Answered by AI
~6 spots leftby Mar 2025